Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Estrella Immunopharma Inc. (ESLAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ESLAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.86% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.09 | 52 Weeks Range 0.03 - 0.19 | Updated Date 02/26/2025 |
52 Weeks Range 0.03 - 0.19 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -174.75% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9097054 |
Shares Outstanding - | Shares Floating 9097054 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Estrella Immunopharma Inc.
Company Overview
History and Background
As of my knowledge cutoff date in early 2023, there is no publicly traded US stock with the name 'Estrella Immunopharma Inc.' Therefore, I cannot provide historical data, milestones, or evolution information. If this is a private company or a newly listed company, information may not be readily available.
Core Business Areas
Leadership and Structure
Without concrete information, leadership and structure details cannot be provided. However, a typical biotech company would have a CEO, CFO, CSO, and a board of directors.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in immunotherapy, is experiencing significant growth driven by technological advancements, aging populations, and increasing prevalence of chronic diseases. Competition is intense, with many companies vying for market share.
Positioning
Without specifics, it's impossible to define Estrella Immunopharma Inc.'s positioning. A successful Immunopharma company must focus on innovative therapies, strong clinical trial results, and efficient commercialization strategies. Competitive advantages would be new drug targets, patents and an efficient route to market.
Total Addressable Market (TAM)
The total addressable market for immunotherapies is estimated to reach hundreds of billions of dollars annually, driven by oncology and autoimmune disease treatments. The company's position within this TAM depends on the success and adoption of its products and therapies.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Strong research and development capabilities
- Experienced management team (Hypothetical)
- Potential for breakthrough therapies
- Strategic partnerships (Hypothetical)
Weaknesses
- High research and development costs
- Regulatory hurdles
- Competition from established players
- Funding requirements
- Clinical trial risks
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals for key products
- Addressing unmet medical needs
Threats
- Patent expirations
- Generic competition
- Changes in healthcare regulations
- Clinical trial failures
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- ABBV
- AMGN
Competitive Landscape
Unable to evaluate Estrella's landscape without specific information. Large pharma companies hold an advantage in the market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data cannot be provided since this company could not be found within public data.
Future Projections: Future projections are unavailable due to the absence of historical data and analyst coverage.
Recent Initiatives: Information on recent initiatives is unavailable.
Summary
Due to the lack of verifiable data for 'Estrella Immunopharma Inc.', a complete analysis is not possible. Based on the hypothetical analysis above, the company would need to focus on innovation and market penetration to become a key player. Funding, regulatory approval, and competition from established companies are significant challenges. Assuming the company exists, further research would need to be carried out.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical analysis based on common knowledge of the biopharmaceutical industry.
- SEC Filings and Investor Relations pages of competitor companies.
Disclaimers:
The information provided is hypothetical and for illustrative purposes only. 'Estrella Immunopharma Inc.' could not be verified as a publicly traded US stock. Market share data is estimated and may not be precise. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Estrella Immunopharma Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2021-09-14 | CEO, President & Director Dr. Cheng Liu Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.estrellabio.com |
Full time employees - | Website https://www.estrellabio.com | ||
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.